Amylyx Pharmaceuticals (AMLX) EBT (2021 - 2026)

Amylyx Pharmaceuticals has reported EBT for 6 years, with the latest figure at -$43.4 million in Q2 2026.

• On a quarterly basis, EBT fell 4.65% year-over-year to -$43.4 million in Q2 2026; TTM through Jun 2026 was -$151.9 million, a 19.29% increase from a year earlier, with the FY2025 full-year figure at -$144.7 million, up 52.11% from the prior year.
• EBT was -$43.4 million for Q2 2026 at Amylyx Pharmaceuticals, down from -$41.2 million in the prior quarter.
• The five-year high for EBT was $24.0 million in Q2 2023, with the low at -$118.6 million in Q1 2024.
• Average EBT over 5 years is -$37.5 million, with a median of -$41.3 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2024: EBT surged 144.55% in 2023, then sank 8549.82% in 2024.
• Over 5 years, EBT stood at -$43.2 million in 2022, then surged by 114.98% to $6.5 million in 2023, then tumbled by 689.58% to -$38.2 million in 2024, then climbed by 13.69% to -$33.0 million in 2025, then sank by 31.61% to -$43.4 million in 2026.
• The last three EBT figures came in at -$43.4 million (Q2 2026), -$41.2 million (Q1 2026), and -$33.0 million (Q4 2025), per Business Quant data.